• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Environ Res Public Health . Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study

tetano

Editor, Senior Moderator
Int J Environ Res Public Health


. 2020 Jul 17;17(14):E5171.
doi: 10.3390/ijerph17145171.
Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain


Beatriz Poblador-Plou[SUP] 1 2 [/SUP], Jon?s Carmona-P?rez[SUP] 1 2 3 [/SUP], Ignatios Ioakeim-Skoufa[SUP] 1 [/SUP], Antonio Poncel-Falc?[SUP] 1 2 4 [/SUP], Kevin Bliek-Bueno[SUP] 1 5 [/SUP], Mabel Cano-Del Pozo[SUP] 1 6 [/SUP], Luis Andr?s Gimeno-Feli?[SUP] 1 2 7 [/SUP], Francisca Gonz?lez-Rubio[SUP] 1 2 3 [/SUP], Mercedes Aza-Pascual-Salcedo[SUP] 1 2 8 [/SUP], Ana Cristina Bandr?s-Liso[SUP] 1 2 4 [/SUP], Jes?s D?ez-Manglano[SUP] 1 9 [/SUP], Javier Marta-Moreno[SUP] 1 2 10 [/SUP], Sara Mucherino[SUP] 11 [/SUP], Antonio Gimeno-Miguel[SUP] 1 2 [/SUP], Alexandra Prados-Torres[SUP] 1 2 [/SUP], EpiChron Group



Affiliations

Abstract

We aimed to analyze baseline socio-demographic and clinical factors associated with an increased likelihood of mortality in men and women with coronavirus disease (COVID-19). We conducted a retrospective cohort study (PRECOVID Study) on all 4412 individuals with laboratory-confirmed COVID-19 in Aragon, Spain, and followed them for at least 30 days from cohort entry. We described the socio-demographic and clinical characteristics of all patients of the cohort. Age-adjusted logistic regressions models were performed to analyze the likelihood of mortality based on demographic and clinical variables. All analyses were stratified by sex. Old age, specific diseases such as diabetes, acute myocardial infarction, or congestive heart failure, and dispensation of drugs like vasodilators, antipsychotics, and potassium-sparing agents were associated with an increased likelihood of mortality. Our findings suggest that specific comorbidities, mainly of cardiovascular nature, and medications at the time of infection could explain around one quarter of the mortality in COVID-19 disease, and that women and men probably share similar but not identical risk factors. Nonetheless, the great part of mortality seems to be explained by other patient- and/or health-system-related factors. More research is needed in this field to provide the necessary evidence for the development of early identification strategies for patients at higher risk of adverse outcomes.

Keywords: COVID-19; Spain; chronic diseases; cohort; comorbidity; drugs; gender; mortality; multimorbidity.
 
Back
Top Bottom